Sponsor Study ID:
A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This study is being done to see if adding brentuximab vedotin helps two drugs work better to treat patients with diffuse large B-cell lymphoma (DLBCL). Participants in this study will have DLBCL that has come back or not gotten better with treatment.
If you would like to contact a MUSC study team member to learn more information about this study, click